HOOKIPA Pharma Inc.: A Leader in Immunotherapeutics against Infectious Diseases and Cancers New York-based clinical stage biopharmaceutical company, HOOKIPA Pharma Inc., is riding high on the success of its proprietary arenavirus platform. The company specializes in developing cutting-edge immunotherapeutics that target infectious diseases and cancers. With a strong focus on research and development, HOOKIPA Pharma Inc. is on a mission to revolutionize healthcare solutions for millions of patients worldwide. The company's lead infectious disease product candidate is HB-101, which is undergoing a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. HOOKIPA's lead oncology product candidates, HB-201 and HB-202, are also making waves with a Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. In a significant development, HOOKIPA recently collaborated with Gilead Sciences, Inc. to explore potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. This partnership holds immense promise for HOOKIPA as it expands its research and development initiatives. HOOKIPA Pharma Inc. was incorporated in 2011 and has become a powerhouse in the biopharmaceutical industry with its innovative approach to healthcare solutions, solidifying its position as a leader in the field.